Article
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Nature communications - 19 Apr 2022
Li Zheqi, McGinn Olivia, Wu Yang, Bahreini Amir, Priedigkeit Nolan M, Ding Kai, Onkar Sayali, Lampenfeld Caleb, Sartorius Carol A, Miller Lori, Rosenzweig Margaret, Cohen Ofir, Wagle Nikhil, Richer Jennifer K, Muller William J, Buluwela Laki, Ali Simak, Bruno Tullia C, Vignali Dario A A, Fang Yusi, Zhu Li, Tseng George C, Gertz Jason, Atkinson Jennifer M, Lee Adrian V, Oesterreich Steffi
Abstract excerpt
Estrogen receptor alpha (ER/ESR1) is frequently mutated in endocrine resistant ER-positive (ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the distinct clinical features of ESR1 mutations, their role in intrinsic subtype switching remains largely unknown. Here we find that ESR1 mutant cells and clinical samples show a significant enrichment of basal subtype markers, and six...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.